Designing gene expression for safer, more effective therapies and more resilient, higher-yielding crops. Annogen was founded in 2017 by Dr. Joris van Arensbergen, as a spin-out of the world-renowned Netherlands Cancer Institute (NKI), where the SuRE™ platform was first developed.
Today, Annogen is an independent research company and the trusted partner of leading biopharmaceutical, agricultural and academic research centers for bespoke gene expression engineering, working through two dedicated arms built on the same SuRE™ platform.
With Annogen B.V., we design gene expression systems for safer, more effective therapies. Using SuRE™, we screen large libraries of regulatory DNA directly in therapeutically relevant human cell types, generating experimental data that goes beyond computational prediction. Every program is shaped in collaboration with you, around the therapeutic gene, cell type, expression level, off-target tissues and model system your therapy requires.
With Annogen Agri B.V., we design gene expression for better, more resilient crops. Using SuRE™, we screen large libraries of a crop’s own regulatory DNA directly in plant-relevant systems, again measured rather than predicted. Every program is shaped in collaboration with you, around the crop, trait, target gene, tissue and condition that matter to your program.
We believe in a future where advanced therapies precisely and durably treat diseases without unintended side effects, and where crops are more resilient, higher yielding and better suited to a changing climate, built on traits that classical breeding alone cannot reach. In both, control of gene expression is a crucial step toward that goal.
Our mission is to become the expertise hub for gene expression engineering, the preferred partner for leading biopharmaceutical, agricultural and academic research centers globally.
Using SuRE™, we redundantly measure the activity of millions of synthetic or genome-derived regulatory elements directly in your target cell type, whether in vitro or in vivo. The versatility of SuRE™ allows us to lift our library into any vector system, best matching your needs.
We analyze the data to find and combine regulatory elements that fit your specification, balancing strength, specificity, and the size your vector allows. Where needed, we perform iterative screening rounds.
The leading candidates are tested in your preferred model system and vector, for example AAV, to confirm the candidates we deliver perform where they matter.
You receive characterized, patentable and ready-to-use regulatory elements with the underlying data, plus support to integrate them into your program.
Joris van Arensbergen, Ph.D.
Founder & CEO
Martijn Kelder, Ph.D.
Chief Strategy Officer
Michelle van Heck
Senior Technician
Weizhen Xu, Ph.D.
Bioinformatics Scientist
Ludo Pagie, Ph.D.
Senior Bioinformatics Scientist
Tijn van Balen, BSc
Junior Scientist
Christiane Llaca, BBA
Operations Manager
Alexey Pindyurin, Ph.D.
Senior Scientist
Daan Peric-Hupkes, Ph.D.
Senior Scientist & Biological Safety Officer
Fleur Prins, MSc
Senior Marketing Consultant
Miriam Smits, BSc
Senior Technician
Work in a close-knit, diverse team focused on delivering top-notch scientific advancements with real-life applications, while maintaining a healthy work-life balance.
We gladly accept internship applications from students enrolled in a relevant academic program with at least 3 months of previous research experience, for a minimum internship period of 9 months for wet-lab work and for a minimum of 6 months for bioinformatics projects.
